The first generation of CRISPR-based therapies showed how the technology can edit DNA, making genetic fixes to unwanted mutations. But those treatments use the CRISPR system as scientists found it in nature, which means it still has limitations when applied to humans, says Benjamin Oakes, CEO of Scribe Therapeutics.

Scribe aims to develop gene-editing therapies that improve CRISPR’s efficacy, safety, and deliverability to target cells. Oakes says Scribe can achieve these goals with technology that imbues a therapy with whatever attributes will make it best suited for a particular application. More than taking what nature provides, Scribe engineers molecules to what… Read more »